Companies › Ascension Health
1 active drug program in 51 registered trials: 19 Phase 4, 17 Phase 3, 12 Phase 2, 3 Phase 1; Neurology, Cardiovascular, Gastroenterology, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tranexamic acid Plasminogen inhibitor | PLG | Phase 2 | Postoperative Blood Loss; Knee Osteoarthritis; Hemorrhage; Melasma … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05047133 | Tranexamic acid | Phase 2 | Postoperative Blood Loss | Other | Jul 2022 |
| NCT05099276 | Tranexamic acid | Phase 4 | Knee Osteoarthritis | Immunology | Dec 2023 |
| NCT07098780 | Tranexamic acid | Phase 4 | Hemorrhage | Metabolic and endocrine | Jul 2025 |
| NCT07034560 | Tranexamic acid | Phase 4 | Melasma | Immunology | Nov 2025 |
| NCT06881628 | Tranexamic acid | Phase 4 | Upper Gastrointestinal Bleeding (UGIB) | Gastroenterology | Dec 2025 |
| NCT06997796 | Tranexamic acid | Phase 1 | Epistaxis Nosebleed | Other | Dec 2025 |
| NCT07263841 | Tranexamic acid | Phase 2 | Post Burn Facial Hyperpigmentation | Immunology | Dec 2025 |
| NCT07263841 | Tranexamic acid | Phase 2 | Post Burn Facial Hyperpigmentation | Immunology | Dec 2025 |
| NCT04233749 | Tranexamic acid | Phase 2 | Lichen Planus Pigmentosus | Immunology | Dec 2025 |
| NCT06023212 | Tranexamic acid | Phase 1 | Metastasis Spinal Tumor | Oncology | Jan 2026 |
| NCT05470816 | Tranexamic acid | Phase 3 | Surgical Site Infection | Infectious disease | Aug 2026 |
| NCT05345613 | Tranexamic acid | Phase 4 | Colon Neoplasm | Oncology | Sep 2026 |
| NCT07460518 | Tranexamic acid | Phase 4 | Benign Prostatic Hyperplasia | Genitourinary | Oct 2026 |
| NCT05836831 | Tranexamic acid | Phase 4 | Intracerebral Hemorrhagic Stroke | Neurology | Nov 2026 |
| NCT06665594 | Tranexamic acid | Phase 2 | Facial Filler Injections | Other | Nov 2026 |
| NCT06109155 | Tranexamic acid | Phase 4 | Surgery, Cardiac | Cardiovascular | Dec 2026 |
| NCT06128330 | Tranexamic acid | Phase 4 | Antifibrinolytic Agents | Other | Dec 2026 |
| NCT04521881 | Tranexamic acid | Phase 3 | Traumatic Brain Injury | Neurology | Dec 2026 |
| NCT04910464 | Tranexamic acid | Phase 3 | Sepsis | Infectious disease | Jan 2027 |
| NCT03552705 | Tranexamic acid | Phase 2 | Anterior Cruciate Ligament Reconstruction | Other | Jan 2027 |
| NCT06450392 | Tranexamic acid | Phase 4 | Orbital Edema | Ophthalmology | Jan 2027 |
| NCT06754371 | Tranexamic acid | Phase 4 | Postpartum Hemorrhage | Immunology | Jan 2027 |
| NCT06229483 | Tranexamic acid | Phase 3 | Brain Tumor | Oncology | Jan 2027 |
| NCT04448184 | Tranexamic acid | Phase 3 | Hematologic Neoplasms | Oncology | Feb 2027 |
| NCT06337838 | Tranexamic acid | Phase 3 | Chronic Kidney Diseases | Genitourinary | Feb 2027 |
| NCT03553186 | Tranexamic acid | Phase 3 | Spinal Deformity | Other | Mar 2027 |
| NCT05713630 | Tranexamic acid | Phase 3 | Subdural Hematoma | Other | Mar 2027 |
| NCT07869537 | Tranexamic acid | Phase 4 | Trauma Coagulopathy | Hematology | Mar 2027 |
| NCT06599762 | Tranexamic acid | Phase 2 | Myelodysplastic Syndromes | Oncology | Apr 2027 |
| NCT06820177 | Tranexamic acid | Phase 4 | Abortion | Other | May 2027 |
| NCT06832878 | Tranexamic acid | Phase 4 | Arthroplasty | Other | Jun 2027 |
| NCT04304625 | Tranexamic acid | Phase 3 | Postpartum Hemorrhage | Other | Jun 2027 |
| NCT03063892 | Tranexamic acid | Phase 4 | Hip Fractures | Other | Jul 2027 |
| NCT02314988 | Tranexamic acid | Phase 2 | Spinal Injuries | Other | Jul 2027 |
| NCT05053867 | Tranexamic acid | Phase 3 | Pulmonary Hemorrhage | Oncology | Jul 2027 |
| NCT02261415 | Tranexamic acid | Phase 3 | Cancer | Oncology | Aug 2027 |
| NCT06057675 | Tranexamic acid | Phase 2 | Postoperative Bleeding | Oncology | Aug 2027 |
| NCT06657924 | Tranexamic acid | Phase 2 | Bleeding | Gastroenterology | Sep 2027 |
| NCT05562609 | Tranexamic acid | Phase 3 | Postpartum Hemorrhage | Other | Sep 2027 |
| NCT05370820 | Tranexamic acid | Phase 2 | Post Partum Hemorrhage | Other | Oct 2027 |
| NCT07893067 | Tranexamic acid | Phase 4 | Melasma (Facial Melasma) | Immunology | Oct 2027 |
| NCT06736860 | Tranexamic acid | Phase 4 | Trauma Coagulopathy | Hematology | Oct 2027 |
| NCT06379724 | Tranexamic acid | Phase 4 | Burns | Other | Dec 2027 |
| NCT06070350 | Tranexamic acid | Phase 3 | Hemorrhagic Shock | Other | Jun 2028 |
| NCT06902714 | Tranexamic acid | Phase 3 | Shoulder Arthroplasty | Immunology | Jul 2028 |
| NCT06519422 | Tranexamic acid | Phase 3 | Anaemia | Hematology | Aug 2028 |
| NCT05899465 | Tranexamic acid | Phase 3 | Melanoma | Oncology | Sep 2028 |
| NCT07245264 | Tranexamic acid | Phase 2 | Chronic Subdural Hematoma | Cardiovascular | Nov 2028 |
| NCT06270407 | Tranexamic acid | Phase 4 | Surgical Complication | Other | Dec 2028 |
| NCT05774717 | Tranexamic acid | Phase 1 | Surgery | Other | Apr 2029 |
| NCT03582293 | Tranexamic acid | Phase 3 | Hematoma, Subdural, Chronic | Cardiovascular | Apr 2029 |
Jiangsu Jingze Biopharmaceutical Novaliq Guangzhou Novaken Pharm Acacia Pharma Laboratorio Elea Phoenix
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.